Ultrarapid clozapine metabolism and CYP2D6 gene duplication in a patient with schizophrenia

Papers of special note have been highlighted as: • of interest

References

• 1 Byerly MJ, Devane CL. Pharmacokinetics of clozapine and risperidone: a review of recent literature. J. Clin. Psychopharmacol. 16(2), 177–187 (1996).
  Medline CASGoogle Scholar
• 2 Carrillo JA, Herraiz AG, Ramos SI, Benitez J. Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients. J. Clin. Psychopharmacol. 18(4), 311–316 (1998).
  Medline CASGoogle Scholar
• 3 Khan AY, Preskorn SH. Examining concentration-dependent toxicity of clozapine: role of therapeutic drug monitoring. J. Psychiatr. Pract. 11(5), 289–301 (2005).
  MedlineGoogle Scholar
• 4 Olesen OV, Linnet K. Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations. J. Clin. Pharmacol. 41(8), 823–832 (2001). • The contributions of CYPs 1A2, 2C19, 3A4, 2C9 and 2D6 to the N-demethylation of clozapine amounted to 30, 24, 22, 12 and 6%, respectively. Clozapine N-demethylation rate suggests that CYP1A2 and CYP2C19 are the most important, while the roles of CYP2C9 and 2D6 are more modest.
  Medline CASGoogle Scholar
• 5 Prior TI, Baker GB. Interactions between the cytochrome P450 system and the second-generation antipsychotics. J. Psychiatry Neurosci. 28(2), 99–112 (2003).
  MedlineGoogle Scholar
• 6 Rajkumar AP, Poonkuzhali B, Kuruvilla A, Srivastava A, Jacob M, Jacob KS. Association between CYP1A2 gene single nucleotide polymorphisms and clinical responses to clozapine in patients with treatment-resistant schizophrenia. Acta Neuropsychiatrica 25(01), 2–11 (2013).
  MedlineGoogle Scholar
• 7 Urichuk L, Prior TI, Dursun S, Baker G. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug–drug interactions. Curr. Drug Metab. 9(5), 410–418 (2008).
  Medline CASGoogle Scholar
• 8 Dragovic S, Gunness P, Ingelman-Sundberg M, Vermeulen NP, Commandeur JN. Characterization of human cytochrome P450s involved in the bioactivation of clozapine. Drug Metab. Dispos. 41(3), 651–658 (2013).
  Medline CASGoogle Scholar
• 9 Eiermann B, Engel G, Johansson I, Zanger UM, Bertilsson L. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br. J. Clin. Pharmacol. 44(5), 439–446 (1997).
  Medline CASGoogle Scholar
• 10 Fischer V, Vogels B, Maurer G, Tynes RE. The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6. J. Pharmacol. Exp. Ther. 260(3), 1355–1360 (1992). • Clozapine binds to the active site of CYP2D6, as demonstrated by the competitive inhibition of dextromethorphan metabolism. The authors concluded that both drug–drug interactions on the binding site of CYP2D6 and polymorphic metabolism of clozapine by CYP2D6 could contribute to the observed variability in clozapine kinetics in humans.
  Medline CASGoogle Scholar
• 11 Linnet K, Olesen OV. Metabolism of clozapine by cDNA-expressed human cytochrome P450 enzymes. Drug Metab. Dispos. 25(12), 1379–1382 (1997).
  Medline CASGoogle Scholar
• 12 Prior TI, Chue PS, Tibbo P, Baker GB. Drug metabolism and atypical antipsychotics. Eur. Neuropsychopharmacol. 9(4), 301–309 (1999).
  Medline CASGoogle Scholar
• 13 Fang J, Baker GB, Silverstone PH, Coutts RT. Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol. Cell Mol. Neurobiol. 17(2), 227–233 (1997).
  Medline CASGoogle Scholar
• 14 Fang J, Mckay G, Song J, Remillrd A, Li X, Midha K. In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes. Drug Metab. Dispos. 29(12), 1638–1643 (2001).
  Medline CASGoogle Scholar
• 15 Kudo S, Ishizaki T. Pharmacokinetics of haloperidol: an update. Clin. Pharmacokinet. 37(6), 435–456 (1999).
  Medline CASGoogle Scholar
• 16 Lovlie R, Daly AK, Molven A, Idle JR, Steen VM. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett. 392(1), 30–34 (1996).
  Medline CASGoogle Scholar
• 17 Steijns LS, Van Der Weide J. Ultrarapid drug metabolism: PCR-based detection of CYP2D6 gene duplication. Clin. Chem. 44(5), 914–917 (1998). • The authors designed PCR assays for the detection of the ultrarapid metabolizer genotype. They found a 3.5% prevalence of ultrarapid metabolizers carrying duplicate active CYP2D6 genes in a population consisting of 202 psychiatric patients.
  Medline CASGoogle Scholar
• 18 Dobrinas M, Cornuz J, Oneda B, Kohler Serra M, Puhl M, Eap CB. Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility. Clin. Pharmacol. Ther. 90(1), 117–125 (2011).
  Medline CASGoogle Scholar
• 19 Melkersson KI, Scordo MG, Gunes A, Dahl ML. Impact of CYP1A2 and CYP2D6 polymorphisms on drug metabolism and on insulin and lipid elevations and insulin resistance in clozapine-treated patients. J. Clin. Psychiatry 68(5), 697–704 (2007).
  Medline CASGoogle Scholar
• 20 Czerwensky F, Leucht S, Steimer W. CYP1A2*1D and *1F polymorphisms have a significant impact on olanzapine serum concentrations. Ther. Drug. Monit. 37(2), 152–160 (2015).
  Medline CASGoogle Scholar
• 21 Gunes A, Ozbey G, Vural EH et al. Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population. Pharmacogenomics 10(5), 769–778 (2009).
  CASGoogle Scholar
• 22 Zanger UM, Eichelbaum M. CYP2D6. Lippincott Williams & Wilkins, PA, USA, 87–94 (2000).
  Google Scholar
• 23 Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 5(1), 6–13 (2005).
  Medline CASGoogle Scholar
• 24 Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin. Pharmacokinet. 48(11), 689–723 (2009). • CYP450 2D6 accounts for only a small percentage of all hepatic CYPs (˜2–4%); however, it metabolizes approximately 25% of current drugs. Typical substrates for CYP2D6 are largely lipophilic bases and include some antidepressants, antipsychotics, antiarrhythmics, antiemetics, β-adrenoceptor antagonists (β-blockers) and opioids.
  Medline CASGoogle Scholar
• 25 Alfaro CL, Lam YW, Simpson J, Ereshefsky L. CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline. J. Clin. Psychopharmacol. 19(2), 155–163 (1999).
  Medline CASGoogle Scholar
• 26 Centorrino F, Baldessarini RJ, Frankenburg FR, Kando J, Volpicelli SA, Flood JG. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am. J. Psychiatry 153(6), 820–822 (1996). • Selective serotonin reuptake inhibitor fluoxetine can increase serum levels of clozapine and norclozapine. It was demonstrated that concentrations of clozapine plus norclozapine averaged 43% higher, and the risk of levels higher than 1000 ng/ml was tenfold greater (25%), in the psychiatric patients taking selective serotonin reuptake inhibitor.
  Medline CASGoogle Scholar
• 27 Joos AA, Konig F, Frank UG, Kaschka WP, Morike KE, Ewald R. Dose-dependent pharmacokinetic interaction of clozapine and paroxetine in an extensive metabolizer. Pharmacopsychiatry 30(6), 266–270 (1997).
  Medline CASGoogle Scholar
• 28 Spina E, Avenoso A, Facciola G et al. Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia. Int. Clin. Psychopharmacol. 13(3), 141–145 (1998).
  Medline CASGoogle Scholar
• 29 Spina E, Avenoso A, Facciola G et al. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology (Berl.) 148(1), 83–89 (2000).
  Medline CASGoogle Scholar
• 30 Taylor D. Pharmacokinetic interactions involving clozapine. Br. J. Psychiatry 171, 109–112 (1997).
  Medline CASGoogle Scholar
• 31 Wetzel H, Anghelescu I, Szegedi A et al. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. J. Clin. Psychopharmacol. 18(1), 2–9 (1998).
  Medline CASGoogle Scholar
• 32 Gregoor JG, Van Der Weide K, Van Der Weide J, Van Megen HJ, Egberts AC, Heerdink ER. The association between CYP2D6 genotype and switching antipsychotic medication to clozapine. Eur. J. Clin. Pharm. 69(11), 1927–1932 (2013).
  Medline CASGoogle Scholar
• 33 Caetano D, Piatkov I. Higher than expected clozapine serum level and clozapine/norclozapine ratio due to CYP450 gene polymorphisms. Personalized Medicine 12(6), 555–558 (2015).
  CASGoogle Scholar
• 34 Meisel C, Roots I, Cascorbi I, Brinkmann U, Brockmoller J. How to manage individualized drug therapy: application of pharmacogenetic knowledge of drug metabolism and transport. Clin. Chem. Lab. Med. 38(9), 869–876 (2000).
  Medline CASGoogle Scholar
• 35 Poolsup N, Li Wan Po A, Knight TL. Pharmacogenetics and psychopharmacotherapy. J. Clin. Pharm. Ther. 25(3), 197–220 (2000).
  Medline CASGoogle Scholar
• 36 Mclellan RA, Oscarson M, Seidegard J, Evans DA, Ingelman-Sundberg M. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics 7(3), 187–191 (1997).
  Medline CASGoogle Scholar
• 37 Friedrich DC, Genro JP, Sortica VA et al. Distribution of CYP2D6 alleles and phenotypes in the Brazilian population. PLoS ONE 9(10), e110691 (2014).
  MedlineGoogle Scholar